Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.24.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenue:    
Contract Revenue $ 1,096 $ 3,188
Costs and Expenses:    
Research and development 14,489 16,678
General and administrative 10,373 11,100
Total costs and expenses 24,862 27,778
Loss from operations (23,766) (24,590)
Sale of New Jersey net operating loss & tax credits 484 3,491
Other income, net 340 102
Net loss $ (22,942) $ (20,997)
Net loss per share - basic $ (0.11) $ (0.10)
Net loss per share - diluted $ (0.11) $ (0.10)
Weighted average common shares outstanding:    
Weighted average common shares outstanding - basic 217,264,526 216,811,439
Weighted average common shares outstanding - diluted 217,264,526 216,811,439
Other comprehensive gain/(loss), net of tax    
Unrealized gain/(loss) on securities available-for-sale $ 603 $ (679)
Other comprehensive gain/(loss), net of tax 603 (679)
Comprehensive loss $ (22,339) $ (21,676)